Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
Mahmut AkgulSean R WilliamsonDilek ErtoyPedram ArganiSounak GuptaAnna CaliòVictor ReuterSatish TickooHikmat A Al-AhmadieGeorge J NettoOndrej HesMichelle S HirschBrett DelahuntRohit MehraStephanie SkalaAdeboye O OsunkoyaLara HarikPriya RaoAnkur R SangoiMaya NouriehDebra L ZyngerSteven Cristopher SmithTipu NazeerBerrak Gümüşkaya ÖcalIbrahim KulacFrancesca KhaniMaria S TretiakovaFunda Vakar-LopezGuliz BarkanVincent MoliniéVirginie VerkarreQiu RaoLorand KisAngel PanizoTed FarzanehMartin J MagersJoseph SanfrancescoCarmen PerrinoDibson GondimRonald AranetaJeffrey S SoJae Y RoMatthew WascoOmar HameedAntonio Lopez-BeltranHemamali SamaratungaSara E WobkerJonathan MelamedLiang ChengMuhammad T IdreesPublished in: Journal of clinical pathology (2021)
Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features.131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up.Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential.Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods.